Results 101 to 110 of about 861 (122)

Preclinical Investigations of Intravitreal Ziv-Aflibercept

Ophthalmic Surgery, Lasers and Imaging Retina, 2014
BACKGROUND AND OBJECTIVE: To investigate the retinal safety of intravitreal (IVT) ziv-aflibercept in rabbits. MATERIALS AND METHODS: Eighteen rabbits were given an IVT injection of ziv-aflibercept (25 mg/mL) or aflibercept (40 mg/mL) and examined by funduscopy, electroretinography ...
João Rafael, de Oliveira Dias, Emmerson, Badaró, Eduardo Amorim, Novais, Daniel, Colicchio, Gabrielly Maria Denadai, Chiarantin, Mariana Maurício, Matioli, Carina, Verna, Fernando Marcondes, Penha, Nilana Meza Tenório, Barros, Carsten H, Meyer, Michel Eid, Farah, Eduardo Büchele, Rodrigues   +11 more
openaire   +2 more sources

Intravitreal Ziv-Aflibercept: A Comprehensive Review

Seminars in Ophthalmology, 2019
Background: Age-related macular degeneration is the leading cause of blindness in adults over the age of 50 in the United States of America. Neovascular age-related macular degeneration (nAMD) is sight-threatening, but can be treated by three currently utilized, intravitreally administered drugs: aflibercept, bevacizumab, and ranibizumab.
Daniel Barmas-Alamdari, Haley S. D’Souza, Kapil G. Kapoor, Alan L. Wagner   +3 more
openaire   +2 more sources

Safety of 5914 intravitreal ziv-aflibercept injections

British Journal of Ophthalmology, 2018
PurposeTo analyse the pooled safety data of intravitreal ziv-aflibercept (IVZ) therapy for various retinal conditions.MethodsThis was a retrospective, observational study which included patients from 14 participating centres who received IVZ. The medical records of patients who received IVZ from March 2015 through October 2017 were evaluated.
Sumit Randhir Singh, Michael W Stewart, Goura Chattannavar, Mohammed Ashraf, Ahmed Souka, Mazen ElDardeery, Neeraj Wadhwa, Chintan Sarvaiya, Ahmad M Mansour, Ameen Marashi, Suresh Ramchandani, Imoro Zeba Braimah, Mohammad Hossein Jabbarpoor Bonyadi, Alireza Ramezani, Masoud Soheilian, João Rafael de Oliveira Dias, Gabriel Costa de Andrade, André Maia, Eduardo Büchele Rodrigues, Michel Eid Farah, Alay Banker, Jay Chhablani   +21 more
openaire   +2 more sources

Two-year outcomes of intravitreal ziv-aflibercept

British Journal of Ophthalmology, 2018
Aim To assess the two-year outcome of intravitreal ziv-aflibercept (IVZ) in eyes with macular diseases. Methods Consecutive subjects with various macular diseases that received six or more of 0.05 mL IVZ (1.25 mg) injections with at ...
Ahmad M Mansour, Mohammed Ashraf, Abdulrazzak Charbaji, Muhammad H Younis, Ahmed A Souka, Avantika Dogra, Hana A Mansour, Jay Chhablani   +7 more
openaire   +2 more sources

SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT

Retina, 2016
To evaluate the safety of intravitreal ziv-aflibercept (Zaltrap) in the treatment choroidal neovascularization secondary to age-related macular degeneration.Eligible eyes with choroidal neovascularization secondary to age-related macular degeneration each received a single intravitreal injection of ziv-aflibercept. Comprehensive ophthalmic examinations
Jay, Chhablani, Raja, Narayanan, Annie, Mathai, Rohit, Yogi, Michael, Stewart   +4 more
openaire   +2 more sources

SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT

Retina, 2017
Purpose: To evaluate the safety of single intravitreal 2 mg ziv-aflibercept (0.08 mL) injections for the treatment of choroidal neovascular membranes (CNVM). Methods: Eyes with choroidal neovascular membranes because of several conditions each received single intravitreal injections
Jay, Chhablani, Chintan Jethalal, Dedhia, Hari K, Peguda, Michael, Stewart   +3 more
openaire   +2 more sources

Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes

Ophthalmic Surgery, Lasers and Imaging Retina, 2018
BACKGROUND AND OBJECTIVE: To study the safety and efficacy of intravitreal injections of ziv-aflibercept (IVI-ZA) (Zaltrap; Sanofi-Aventis and Regeneron Pharmaceuticals, Tarrytown, NY) during a period of 48 weeks in patients with diabetic macular edema (DME).
Gabriel Costa, de Andrade, João Rafael, de Oliveira Dias, André, Maia, Michel Eid, Farah, Carsten H, Meyer, Eduardo Buchele, Rodrigues   +5 more
openaire   +2 more sources

Ziv-aflibercept (Zaltrap) for the Treatment of Metastatic Colorectal Cancer

Annals of Pharmacotherapy, 2013
Objective: Review pharmacology, pharmacokinetics, efficacy, and safety of ziv-aflibercept in combination with FOLFIRI for treatment of metastatic colorectal cancer (mCRC) resistant to or progressed following oxaliplatin-containing regimens. Data Sources: Articles indexed in PubMed (1948-August 2013), TOXLINE (2001-August 2013), and Google Scholar as ...
Scott L, Perkins, Sabrina W, Cole
openaire   +2 more sources

Analytical comparability assessment on glycosylation of ziv-aflibercept and the biosimilar candidate

International Journal of Biological Macromolecules, 2021
Ziv-aflibercept (aflibercept) is a recombinant fusion protein which combines the portions of human vascular endothelial growth factor receptors extracellular domains fused to the Fc portion of human IgG1. It is a highly sialylated glycoprotein with 5 N-glycosylation sites.
Zhenduo, Shen, Yanhong, Wang, Huarong, Xu, Qian, Zhang, Chunjie, Sha, Baiping, Sun, Qing, Li   +6 more
openaire   +2 more sources